Connor Clark & Lunn Investment Management Ltd. Purchases 79,602 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Connor Clark & Lunn Investment Management Ltd. boosted its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 35.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 302,536 shares of the biopharmaceutical company’s stock after acquiring an additional 79,602 shares during the period. Connor Clark & Lunn Investment Management Ltd.’s holdings in Amicus Therapeutics were worth $2,850,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. KBC Group NV increased its position in shares of Amicus Therapeutics by 44.4% during the fourth quarter. KBC Group NV now owns 10,154 shares of the biopharmaceutical company’s stock worth $96,000 after purchasing an additional 3,120 shares in the last quarter. Legacy Capital Group California Inc. grew its stake in Amicus Therapeutics by 20.2% during the 4th quarter. Legacy Capital Group California Inc. now owns 23,229 shares of the biopharmaceutical company’s stock worth $219,000 after buying an additional 3,900 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new position in Amicus Therapeutics during the 3rd quarter valued at about $55,000. China Universal Asset Management Co. Ltd. raised its stake in Amicus Therapeutics by 11.1% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 63,358 shares of the biopharmaceutical company’s stock valued at $597,000 after buying an additional 6,314 shares during the last quarter. Finally, Los Angeles Capital Management LLC boosted its holdings in Amicus Therapeutics by 46.3% in the third quarter. Los Angeles Capital Management LLC now owns 20,474 shares of the biopharmaceutical company’s stock worth $219,000 after acquiring an additional 6,484 shares in the last quarter.

Analyst Ratings Changes

Several brokerages recently commented on FOLD. Wells Fargo & Company decreased their price objective on shares of Amicus Therapeutics from $18.00 to $17.00 and set an “overweight” rating for the company in a research report on Thursday, February 20th. StockNews.com cut shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, February 20th. Cantor Fitzgerald reissued an “overweight” rating and set a $21.00 price objective on shares of Amicus Therapeutics in a report on Wednesday, January 15th. Morgan Stanley restated an “equal weight” rating and issued a $12.00 target price (down previously from $17.00) on shares of Amicus Therapeutics in a research note on Friday, December 13th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Amicus Therapeutics in a research note on Thursday, February 20th. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $16.75.

Amicus Therapeutics Stock Performance

NASDAQ FOLD opened at $9.12 on Tuesday. The firm has a market capitalization of $2.80 billion, a P/E ratio of -50.67, a PEG ratio of 1.51 and a beta of 0.69. The stock has a 50-day simple moving average of $9.37 and a two-hundred day simple moving average of $10.13. The company has a debt-to-equity ratio of 2.01, a quick ratio of 2.42 and a current ratio of 3.39. Amicus Therapeutics, Inc. has a fifty-two week low of $8.55 and a fifty-two week high of $12.65.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.